Compare NIO Inc. (NIO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Tango Therapeutics Inc. — how do they compare? NIO Inc. trades at $3.4 (market cap $8.54B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: NIO Inc. is far larger — about 2.3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Tango Therapeutics Inc. for 0 Days on average.
| NIO | TNGX | |
|---|---|---|
Market Cap | $8.54B | $3.75B |
Volume | 34,684,903 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.42 | $32.90 |
52-Week Low | $3.37 | $7.50 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $6.43B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.41, down 1.73% on the day and near its 52-week low, reflecting a bearish technical trend. The company reported a net loss of $15.57 billion in 2025, though revenue grew to $87.49 billion and the net loss margin improved to -17.8%. Recent news highlights a strategic battery-swapping partnership with Geely, which could expand NIO's network but has weighed on the stock as investors assess profitability ahead of Q3 2026 earnings.
The outlook remains challenging due to persistent losses and intense EV competition, but analyst consensus is a Buy with a $6.23 price target, suggesting significant upside. Key risks include high debt, cash burn, and price wars in China's EV market, while opportunities lie in scaling the battery-swap network and potential margin improvement if delivery growth continues.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
